Table 4.

Data on common gastrointestinal side effects of different incretin-based therapies as compared to placebo, pooled from different published systematic reviews and meta-analyses

	Number of Trials	Nausea OR (95%CI)	Vomiting OR (95%CI)	Diarrhoea OR (95%CI)
Cagrilintide vs Placebo *	This meta-analysis	0.97 (0.54–480.32)	3.16 (0.83–12.04)	2.19 (0.93–5.14)
Semaglutide vs Placebo (25)	17 (n=6756)	2.82 (2.56–3.81)	3.79 (2.77–5.19)	1.90 (1.65–2.19)
Tirzepatide vs Placebo (7)	3 (n=594)	3.02 (1.51–6.05)	3.63 (1.13–11.67)	3.17 (1.64–6.15)

*Data comparing Cagrisema to placebo is currently not available, hence not presented here; OR: Odds ratio; CI: confidence interval